OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Fenske on the Omission of ASCT in Mantle Cell Lymphoma After First CR and uMRD

January 10th 2025

Timothy S. Fenske, MD, MS, discusses implications for data on the omission of auto-HCT in MCL after first CR and with undetectable MRD.

Dr Lotan on the Benefits and Complications Associated With Radical Cystectomy in BCG-Unresponsive NMIBC

January 10th 2025

Yair Lotan, MD, discusses the benefits and complications associated with radical cystectomy for patients with BCG-unresponsive NMIBC.

Dr Dronca on the FDA Approval of Subcutaneous Nivolumab in Solid Tumors

January 9th 2025

Roxana S. Dronca, MD, discusses the FDA’s approval of subcutaneous nivolumab across solid tumor indications.

Dr Eckfeldt on the Treatment Paradigm and Current Challenges in MDS

January 9th 2025

Craig Eckfeldt, MD, PhD, discusses the current treatment paradigm in MDS and the unmet needs in different subsets of patients.

Dr Goldsberry on PARP Inhibitor Selection in Advanced Ovarian Cancer

January 9th 2025

Whitney Goldsberry, MD, discusses considerations for selecting a PARP inhibitor in the maintenance treatment of ovarian cancer.

Dr Riess on the Investigation of Ivonescimab in Advanced NSCLC

January 9th 2025

Jonathan Wesley Riess, MD, MS, discusses data from the phase 3 HARMONi-2 trial evaluating ivonescimab vs pembrolizumab in advanced NSCLC.

Dr Lotan on the Future Research Directions in BCG-Unresponsive NMIBC

January 9th 2025

Yair Lotan, MD, discusses the evolving treatment paradigm for Bacillus Calmette-Guérin–unresponsive non–muscle-invasive bladder cancer.

Dr Huppert on Survival Outcomes of Patients With Metastatic Breast Cancer and Leptomeningeal Disease

January 9th 2025

Laura A. Huppert, MD, discusses survival outcomes of patients with metastatic breast cancer and leptomeningeal disease according to disease subtype.

Dr Niravath on Durvalumab, Trastuzumab, and Pertuzumab in HER2-Enriched Breast Cancer

January 9th 2025

Polly Niravath, MD, discusses a chemotherapy-free regimen of durvalumab, trastuzumab, and pertuzumab in HER2-enriched early breast cancer.

Dr Dasari on the Evolving Treatment Paradigm in mCRC

January 8th 2025

Arvind N. Dasari, MD, MS, discusses the roles for the FDA-approved agents fruquintinib and TAS-102 plus bevacizumab in the mCRC treatment paradigm.

Dr Geyer on the Efficacy of Perioperative Atezolizumab Plus Chemotherapy in Stage II/III TNBC

January 8th 2025

Charles E. Geyer, Jr., MD, discusses the efficacy and safety of perioperative atezolizumab plus chemotherapy in stage II/III triple-negative breast cancer.

Dr Neelapu on 5-Year Data for Axi-Cel in R/R Follicular Lymphoma and MZL

January 8th 2025

Sattva S. Neelapu, MD, discusses a 5-year follow-up data for axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma.

Dr Alencar on the Preliminary Efficacy and Safety of NX-5948 in CLL

January 8th 2025

Alvaro Alencar, MD, discusses the preliminary efficacy and safety of NX-5948, a BTK degrader, in patients with chronic lymphocytic leukemia.

Dr Shallis on Data for Pembrolizumab Plus Venetoclax/Azacitidine in AML

January 8th 2025

Rory Shallis, MD, discusses the addition of pembrolizumab to azacitidine citidine and venetoclax in patients with acute myeloid leukemia.

Dr Nasioudis on the Potential for XPO1 Inhibition in TP53 Wild-Type Ovarian Cancer

January 8th 2025

Dimitrios Nasioudis, MD, discusses preclinical study findings utilizing XPO1 inhibition for TP53 wild-type low-grade serous and clear cell ovarian cancer.

Dr Borgen on the Use of AI to Support Treatment Decision-Making in Oncology

January 7th 2025

Patrick Borgen, MD, discusses how advances in artificial intelligence may influence the future of oncology practice.

Dr Borgen on the Strengths and Limitations of AI in Oncology Practice

January 7th 2025

Patrick I. Borgen, MD, discusses research outlining the current clinical applications and limitations of artificial intelligence in oncology practice.

Dr Brem on Odronextamab in Previously Untreated Patients, High-Risk Follicular Lymphoma

January 7th 2025

Elizabeth Brem, MD, discusses data for odronextamab monotherapy in previously untreated patients with high-risk follicular lymphoma.

Dr DeAngelo on the FDA Approval of Blinatumomab Consolidation in CD19+, Ph– B-ALL

January 7th 2025

Daniel DeAngelo, MD, PhD, discusses the FDA approval of blinatumomab in the consolidation phase in CD19-positive, Ph-negative B-cell precursor ALL.

Dr DeAngelo on the Effect of Avapritinib on Bone Density in Advanced Systemic Mastocytosis

January 7th 2025

Daniel DeAngelo, MD, PhD, discusses the effect of avapritinib on bone density in patients with advanced systemic mastocytosis.